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Abstract
Liver is unique in its capacity to regenerate in response to 
injury or tissue loss. Hepatocytes and other liver cells are 
able to proliferate and repopulate the liver. However, when 
this response is impaired, the contribution of hepatic 
progenitors becomes very relevant. Here, we present an 
update of recent studies on growth factors and cytokine-
driven intracellular pathways that govern liver stem/pro-
genitor cell expansion and differentiation, and the rel-
evance of these signals in liver development, regeneration 
and carcinogenesis. Tyrosine kinase receptor signaling, 
in particular, c-Met, epidermal growth factor receptors or 
fibroblast growth factor receptors, contribute to prolifera-
tion, survival and differentiation of liver stem/progenitor 
cells. Different evidence suggests a dual role for the trans-
forming growth factor (TGF)-β signaling pathway in liver 
stemness and differentiation. On the one hand, TGF-β 
mediates progression of differentiation from a progenitor 
stage, but on the other hand, it contributes to the expan-
sion of liver stem cells. Hedgehog family ligands are nec-
essary to promote hepatoblast proliferation but need to be 
shut off to permit subsequent hepatoblast differentiation. 
In the same line, the Wnt family and β-catenin/T-cell fac-
tor pathway is clearly involved in the maintenance of liver 
stemness phenotype, and its repression is necessary for 
liver differentiation during development. Collectively, data 
indicate that liver stem/progenitor cells follow their own 
rules and regulations. The same signals that are essential 
for their activation, expansion and differentiation are good 
candidates to contribute, under adequate conditions, to 
the paradigm of transformation from a pro-regenerative 
to a pro-tumorigenic role. From a clinical perspective, this 
is a fundamental issue for liver stem/progenitor cell-based 
therapies.
© 2010 Baishideng. All rights reserved.
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to injury or tissue loss. Following two-thirds partial hepa-
tectomy, hepatocytes exit the G0 phase of  the cell cycle 
and synchronously re-enter the cell cycle to regenerate 
the liver mass completely in 6-7 d in rodents, or 3-4 mo 
in humans[1-4]. Liver stem/progenitor cells do not seem 
to be required for this process. However, when this re-
sponse is impaired, as in the case of  a hepatocyte-selective 
proliferative defect or acute liver failure, the contribution 
of  liver progenitors becomes much more relevant[5,6]. A 
population of  small cells with a low cytoplasmic/nuclear 
ratio that arose from a small number of  portal cells, not 
from hepatocytes, were first observed in rodents and 
became known as “oval cells”[7,8]. Although several lines 
of  evidence suggest that oval cells derive from the biliary 
compartment, other origins have been also suggested[4].
Significant work in the past few years has focused on 
the signaling pathways, as well as cell-cell interactions, that 
control the initial proliferation/expansion and the termi-
nal differentiation of  liver stem/progenitor cells. Oval 
cells express MET, the receptor of  the hepatocyte growth 
factor (HGF). The superabundance of  HGF-producing 
cells in the immediate vicinity of  oval cell proliferation 
and differentiation suggests that this growth factor is in-
volved in all aspects of  stem cell behavior, proliferation, 
migration, and differentiation, through a paracrine mecha-
nism[9]. Oval cells also express receptors for epidermal 
growth factor (EGF)-like ligands, and in vivo infusion of  
a combination of  HGF and EGF enhance the mitogenic 
response of  oval cells after administration of  2-acetylami-
nofluorene[10], which reveals the relevance of  both growth 
factors in liver stem/progenitor cell biology. Additionally, 
different studies have revealed that oval cells also respond 
to other growth factors in an autocrine/paracrine man-
ner[11]. The transforming growth factor (TGF)-β family 
of  cytokines play a relevant role in the maintenance of  
embryonic stem cell identity, and it has been shown that 
the specification of  pancreas and liver progenitors is re-
stricted by the TGF-β pathway[12]. All these growth factors 
and cytokines might modulate not only proliferation of  
liver stem/progenitor cells, but also cell death, as well as 
contributing to their terminal differentiation. 
This review gives an update on recent relevant stud-
ies of  the growth factors and cytokine-driven intracellular 
pathways that govern liver stem/progenitor cell expansion 
and differentiation, and the relevance of  these signals in 
liver development, regeneration and carcinogenesis.
TYROSINE KINASE RECEPTOR-MEDIATED 
SIGNALING PATHWAYS
HGF
HGF was firstly identified in the 1980s as a potent mito-
gen for hepatocytes[13-15]. A factor secreted by fibroblasts 
and smooth muscle cells was discover separately, which 
promoted epithelial cell scattering[16]. Later studies un-
raveled that HGF and scatter factor were indistinguish-
able[17,18]. HGF is a growth factor that induces a wide 
range of  biological activities, including stimulation of  
proliferation, migration, morphogenesis, and survival of  
a variety of  cell types[19-24], which plays a major role in tis-
sue formation and homeostasis. HGF acts through bind-
ing to its tyrosine kinase receptor, Met. Ligand-receptor 
binding results in autophosphorylation of  the receptor 
in specific tyrosine residues located in the C-terminal 
domain, and subsequent phosphorylation/activation of  
multiple adapter and signal transducing proteins, such 
as growth factor receptor-bound protein 2 (Grb2)/Sos, 
Ras-mitogen-activated protein kinase, Grb2-associated 
binding protein 1 (Gab1), phosphoinositide 3-kinase 
(PI3K), phospholipase C-γ, p38, and signal transducer 
and activator of  transcription (STAT)-3, among oth-
ers, which mediate the biological activities of  HGF/
c-Met[25,26]. For decades, HGF has been recognized as a 
growth factor involved in the hepatocyte proliferative re-
sponse during liver regeneration (a recent review on the 
role of  HGF in liver regeneration can be found in[3]), but 
an unequivocal demonstration of  an essential role of  the 
HGF/c-Met signaling in liver regeneration has only been 
provided recently. Thus, liver specific c-Met and HGF 
conditional knock-out mice show an impairment of  the 
regenerative response[27-29]. Hepatocytes that lack a func-
tional c-Met display reduced basal survival and a higher 
sensitivity to Fas-induced liver damage, both in vivo and 
in vitro. Moreover, after toxic liver injury induced by ex-
posure to CCl4, c-met-/- livers showed delayed healing 
from necrotic injury[28]. Complete abolition of  the cell 
cycle has also been demonstrated when c-Met is deleted 
after partial hepatectomy, by using RNA interference 
techniques[30]. In addition to the effects on proliferation, 
these authors have described an alteration in expression 
of  apoptosis-related genes, particularly, increased expres-
sion of  pro-apoptotic genes, and decreased expression 
of  anti-apoptotic genes, and enhanced activation of  cas-
pase 3. Altogether, these studies provide clear evidences 
of  a role for this ligand/receptor system in promoting 
hepatocyte proliferation, survival, and tissue remodeling 
during liver regeneration. 
HGF/c-Met signaling is also essential during fetal liver 
development. Both HGF- and c-Met-deficient embryos 
show abnormally small livers and liver-to-body weight 
ratios and massive hepatocyte apoptosis[31-33]. Recent 
studies from Dr. Maina’s laboratory have demonstrated 
HGF/c-Met survival properties in primary embryonic 
hepatocytes, as shown by the ability of  HGF to impair 
Fas-induced apoptosis by acting through PI3K and AKT 
to prevent FLICE inhibitory protein degradation[34]. Ad-
ditionally, in the context of  the adult liver, numerous 
works have reported an important contribution of  the 
pro-survival activity of  HGF in protecting liver during 
fibrosis and other hepatic dysfunction[35-40], thus expanding 
the scenarios in which the anti-apoptotic activity of  HGF 
plays an active role. 
Although hepatocytes have long been considered the 
prime target of  the actions of  HGF, there is accumulating 
evidence of  an important role for HGF/c-Met signaling 
on liver stem/progenitor cell function and behavior. Liver 
stem/progenitor cells express c-met[41]. Furthermore, 
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during oval cell activation induced by N-acetyl-2-amino-
fluorene/partial hepatectomy (AAF/PH) in rats, HGF 
expression increases coincidentally with oval cell prolifera-
tion, mainly on the periportal regions where oval cells are 
located[9,41]. These data suggest that the HGF/c-Met sys-
tem regulates some aspects of  liver stem/progenitor cell 
biology. In support of  this, in vivo infusion of  HGF dur-
ing AAF/PH-induced liver regeneration stimulates oval 
cell expansion into the liver lobules[10]. Similar results have 
been obtained by in vivo transfer of  HGF cDNA into liver 
subjected to the Solt-Farber regime[42]. HGF-dependent 
mitogenic activity has also been shown in rat and mouse 
oval cell lines in vitro by either adenovirus-mediated trans-
fer of  the HGF gene or addition of  exogenous HGF[43-46]. 
The molecular mechanisms that mediate the mitogenic 
effects of  HGF in liver progenitors appear to be cell-type 
specific, because PI3K/AKT activation[43] and nuclear 
factor-κB activation, downstream of  p38 and extracellular 
signal-regulated kinase (ERK) MAPKs[44], are involved. 
Additionally, bi-potential hepatoblast cell lines (precursors 
of  both hepatocytes and cholangiocytes) have been estab-
lished from transgenic animals expressing a constitutively 
active human Met[47]. However, HGF is much more than 
a mitogen for liver stem/progenitor cells. HGF effectively 
protects WB-F344 cell from apoptosis induced by tumor 
necrosis factor-α in a dose-dependent manner[44]. More re-
cently, using a novel in vitro model of  genetically modified 
oval cells that harbor an inactivated Met tyrosine kinase, 
we have demonstrated that loss of  Met increases sensitiv-
ity to apoptosis caused by serum deprivation or treatment 
with TGF-β[46]. By virtue of  these results, we hypothesize 
that Met-driven anti-apoptotic activity plays an impor-
tant role supporting the expansion of  liver progenitors 
following liver injury, by helping them to overcome the 
local tissue injuries and inhibitory signals. Therefore, the 
HGF/c-Met signaling pathway might be a major survival 
pathway in liver that operates during liver development, 
homeostasis, and regeneration (both hepatocyte and oval 
cell-mediated). 
The role of  HGF as a morphogen is already estab-
lished[48]. Morphogenesis is a complex invasive growth 
program that plays a fundamental role in normal develop-
ment[49,50]. Not surprisingly, morphogenic properties of  
HGF are exhibited in embryonic and postnatal mouse 
non-parenchymal epithelial cell-derived cell lines. In these 
cells, HGF induces a morphogenic response that includes 
cell scattering and ductal branching in collagen gels. These 
changes are not observed by treatment with other liver 
growth factors including EGF, TGF-β, acidic fibroblast 
growth factor (aFGF) and insulin, and are not inhibited 
by TGF-β[51]. A similar response has also been described 
in pancreatic oval cells in vitro; a cell population closely re-
lated to its hepatic counterpart[52]. Recently, HGF has been 
directly involved in promoting motility and invasiveness 
of  human liver progenitor cells through Matrigel; an ef-
fect that is partially mediated by matrix-metalloproteinase-
mediated extracellular matrix (ECM) proteolytic degrada-
tion and activation of  the MAPK/ERK pathway[53].
Another important biological activity of  HGF in liver 
progenitor cells that cannot be overlooked is its modula-
tory effect on the differentiation capacity of  these cells. 
HGF has been reported to be required not only for an 
efficient proliferation and survival, but for hepatocytic dif-
ferentiation of  embryonic hepatic stem cells in vitro[54-57]. 
Furthermore, virtually all the strategies for in vitro dif-
ferentiation of  embryonic and adult stem/progenitor 
cells of  different origin into hepatocytes include HGF 
as a hepatic-inducing factor (a thorough compilation of  
in vitro differentiation methods is found in[58]). Successful 
differentiation is generally achieved by step by step addi-
tion of  growth factors, cytokines, and hormones, trying to 
emulate the sequence of  events taking place during in vivo 
hepatogenesis. The requirement of  HGF in this process 
relies on the specific role played by this growth factor at 
different liver developmental stages. During the commit-
ment phase, HGF might antagonize differentiation of  bi-
potential hepatoblasts along the cholangiocytic lineage, 
which results in support of  growth and differentiation 
of  fetal hepatocytes[59]. In fact, results from Suzuki et al[57] 
have demonstrated that HGF can initiate differentiation 
of  albumin-negative liver stem cells into albumin-positive 
hepatic precursors at the same time that allows their 
expansion and decreases expression of  cholangiocyte-
lineage markers, such as CK19 or γ-glutamyl transferase, 
but it cannot induce latter markers of  hepatocyte differen-
tiation, such as glucose-6-phosphatase or tryptophan-2,3-
dioxygenase. 
Later, after birth, the expression of  both HGF and c-Met 
significantly increases in the liver, and activation of  this 
pathway crucially assists during complete functional he-
patic maturation[41,60]. We have also described that HGF 
combined with TGF-β helps to maintain the expression 
of  hepatocyte differentiation markers in rat fetal hepato-
cytes in culture[61,62]. In rat primary neonatal hepatocytes, 
HGF promotes scattering, but this effect is not associated 
with a dedifferentiation process, as shown by an increase 
in the expression of  hepatic differentiation markers using 
HGF treatment[63,64]. Although a role for HGF in hepato-
cyte differentiation seems to be beyond reasonable doubt, 
it should be pointed out that HGF has also been directly 
implicated in transdifferentiation of  hepatocytes to bili-
ary epithelial cells[65]. These data highlight the enormous 
complexity in terms of  signaling networks and molecular 
mechanisms associated with regulation of  phenotypic 
transitions in liver epithelial cells.
All these results provide sufficient evidence to support 
a crucial role for an HGF/c-Met-induced signaling path-
way in liver stem/progenitor cell biology. What it is not 
totally clear, however, is its mode of  action. HGF is mainly 
produced by mesenchymal cells, and c-Met is expressed in 
epithelial cells, therefore, this ligand-receptor system is gen-
erally considered to act in a paracrine fashion[66]. Consistent 
with this, the main producers of  HGF in the liver are the 
stellate cells[67,68], although sinusoidal endothelial cells also 
express HGF[69]. c-Met is expressed in hepatocytes, biliary 
epithelial cells, and liver progenitor cells[41,54,70,71]. As men-
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tioned above, in rat models of  oval cell activation in vivo, 
HGF mRNA has been identified in the desmin-positive 
stellate cells that surround the ductal structures of  oval 
cells, or interspersed with the oval cells, whereas c-Met 
expression is detected in oval cells[9,41]. These results have 
prompted the conclusion that the HGF/c-Met system 
operates in oval cells via a paracrine mechanism. However, 
in vitro studies carried out in our laboratory in oval cell lines 
have shown an autocrine regulatory mechanism for HGF/
c-Met involved in protection against apoptosis[46]. Whether 
the autocrine regulation plays a role in vivo has not been ex-
plored, but these data suggest that oval cells might respond 
to both autocrine and paracrine Met signaling in a context-
dependent fashion.
EGF receptor ligands
Another tyrosine kinase receptor family that regulates 
liver pathophysiology is the EGF receptor (EGFR) fam-
ily. This receptor is part of  a complex signaling system 
that includes multiple ligands, namely TGF-α, EGF, hep-
arin-binding EGF, amphiregulin, betacellulin, epiregulin, 
epigen, and crypto; and four transmembrane receptors: 
EGFR (Her1/ErbB-1), ErbB-2 (Her2/neu), ErbB-3 
(Her3), and ErbB-4 (Her4). Complexity of  this pathway 
relies on differential ligand binding affinity to the recep-
tors, as well as formation of  receptor homo- and hetero-
dimers, all of  which leads to activation of  distinct intra-
cellular signaling cascade and diverse biological activities. 
Among all the ligands, TGF-α and EGF are the most 
widely studied. Both TGF-α and EGF bind and activate 
the same receptor, EGFR. Ligand binding results in 
dimerization and autophosphorylation of  EGFR in ty-
rosine residues of  the cytoplasmic domain. This leads to 
recruitment of  adapter proteins, such as Grb2 and Shc, 
and subsequent activation of  multiple downstream path-
ways, including PI3K, Ras-MAPK, c-Jun N-terminal ki-
nase, p38, protein kinase C and STAT-3, which mediate 
cell proliferation, migration, differentiation and evasion 
from apoptosis[72-76]. TGF-α and EGF are well-known 
regulators of  hepatocyte proliferation. Infusion of  either 
one of  the two factors initiates DNA synthesis in liver 
of  adult rats[77,78], and when added exogenously, they 
stimulate growth of  primary hepatocytes at all develop-
mental stages: fetal, neonatal, and adult[79-82]. Together 
with HGF, EGFR ligands represent the only complete 
mitogens in adult hepatocytes in serum-free medium, 
and the most important growth factors involved in the 
proliferative response during liver regeneration[3]. Dem-
onstration of  a critical role for EGFR in hepatocyte 
proliferation during the initial phases of  liver regenera-
tion has recently been provided by generating mice with 
a liver-specific EGFR deficiency[83]. In addition to the 
regulatory role in proliferation, and similarly to Met, 
EGFR is a major survival pathway in the liver[84]. EGF-
mediated EGFR activation is able to abolish completely 
the apoptotic response induced by TGF-β in fetal rat 
hepatocytes[62] or by Fas receptor stimulation in mouse 
hepatocytes[85]. Furthermore, EGFR ligands appear to 
be important modulators of  hepatocyte differentiation 
as well. Morphological and gene expression studies from 
our laboratory and collaborators have shown that EGF, 
acting in cooperation with other cytokines and hor-
mones, maintains primary fetal and neonatal hepatocyte 
differentiation[64,86,87]. 
Expression studies have suggested that ErbB1-triggered 
signaling also plays a role in stem/progenitor-cell-mediated 
liver regeneration. Indeed, both TGF-α and EGFR are 
transcriptionally upregulated during the period of  active 
proliferation and differentiation of  progenitor cells in the 
rat liver subjected to the 2-AAF/PH protocol[88], and they 
appear to drive the early proliferation of  the progenitor 
cell compartment[89,10]. Although both HGF and EGF pro-
mote the expansion of  oval cells in vivo, some differences 
are observed. HGF increased number of  both ductal and 
Ito cells at a similar rate, whereas infusion of  EGF mostly 
increases ductal cells. Our laboratory and others have also 
shown that EGF and TGF-α are mitogens in mouse and 
rat oval cells in vitro[11,46,90].
The effects of  this signaling pathway on liver stem/
progenitor cells are not restricted to mitogenesis. In vivo 
infusion with either EGF or HGF not only amplifies liver 
progenitor expansion following liver injury but also de-
creases apoptosis[10]. We also have evidence of  an impor-
tant role for EGFR-mediated signaling in regulating oval 
cell survival in vitro. Thus, inhibition of  EGFR via treat-
ment with a synthetic inhibitor increases basal apoptosis (in 
the absence of  serum and exogenous stimuli) and strongly 
amplifies TGF-β-induced apoptosis (our unpublished 
results). EGFR-mediated motogenic, morphogenic, and 
differentiation activities have also been reported. EGF, 
combined with TGF-β, triggers a scattering response in 
mouse oval cell lines in vitro[11]. In addition to this, EGF 
is often included as a hepatogenic factor in strategies to 
induce in vitro differentiation of  stem/progenitor cells into 
hepatocyte-like cells[58]. Consistently, TβT-FH cell lines - 
a cell population of  fetal hepatocytes that has suffered 
an epithelial mesenchymal transition (EMT) and a dedif-
ferentiation process after TGF-β treatment - recover the 
original epithelial phenotype and gain cytokeratin-19 ex-
pression by treatment with EGF and DMSO, which sug-
gests conversion to hepatoblast-like cells[91]. 
It should be noted that we have seen autocrine regula-
tion for EGFR-dependent signaling in oval cell lines (our 
unpublished results). Different to the HGF/c-Met system, 
an EGFR-ligand-mediated autocrine mechanism has been 
suggested, based on the detection of  EGFR ligand tran-
scripts in oval cells during liver regeneration[88]. In vivo and 
in vitro studies have shown that choline-deficient ethio-
nine-supplemented diet-treated mouse livers express cyto-
kines such as lymphotoxin-β, interferon-γ, and interleukin 
(IL)-6[92,93]. Collectively, these data strongly support that 
autocrine regulatory mechanisms are important in liver 
progenitor cells. The significance of  the c-Met and EGFR 
autocrine loops in oval cells is not yet totally understood. 
Certainly, autocrine signaling has been mostly associated 
with malignancy. This seems to apply to stem/progenitor 
Sánchez A et al . Signaling in liver stem cells
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cells as well, because tumorigenic conversion of  mouse 
oval cell has been associated with growth factor produc-
tion and alteration in growth factor responsiveness[11]. 
More specifically, an HGF/c-Met autocrine loop has been 
identified in spontaneously transformed WB-F344 rat liv-
er stem-like cells, which contributes to drive autonomous 
cell proliferation[94]. Spontaneously transformed oval cells 
express TGF-α. These cells form tumors when injected 
into nude mice, a capacity that is significantly reduced by 
transfection with TGF-α antisense gene[95]. A cross-talk 
between Met and EGFR has also been proposed. Thus, 
rat liver-epithelial-cell-derived tumor cell lines that consti-
tutively express TGF-α display increased levels of  both 
c-met gene and protein, as well as an amplified response 
to HGF[96]. However, 3,5-diethoxycarbonyl-1,4-dihydro-
collidine (DDC)-treated mouse liver-derived oval cell 
lines, which show autocrine activation of  Met and EGFR-
dependent pathways, do not show any sign of  transfor-
mation[46] (and our unpublished results). Whether this is 
due to a matter of  time, dose, or lack of  critical partners 
for the neoplastic transformation, it is not yet known. For 
now, awaiting further conclusive experiments, a direct link 
between the establishment of  functional c-Met and EG-
FR-dependent autocrine loops and neoplastic transforma-
tion cannot be firmly established in liver progenitor cells. 
All the data summarized above highlight not only a 
relevant role of  Met and EGFR-triggered signaling path-
ways in regulating the liver progenitor cell compartment, 
but a striking parallelism between the two pathways, both 
of  which mediate growth, survival, migration and hepato-
cytic differentiation (Figure 1). Further studies will clarify 
which of  these biological activities are totally overlapping 
and which are not. In this sense, Met and EGFR mutant 
mice and cell models should provide very useful and in-
valuable tools in this regard.
FGFs
The FGFs are a family of  growth factors with high affin-
ity for heparan sulfate proteoglycans, which bind to trans-
membrane tyrosine kinase FGF receptors (FGFRs). The 
role of  these growth factors in hepatic fate specification 
of  pre-hepatic endoderm cells during liver development is 
well known. There are a number of  excellent reviews on 
this subject, some of  which are cited here[97-99]. Activation 
of  adult stem/progenitor cells is believed to use similar, 
if  not identical, genetic programs as the embryonic pro-
genitors, therefore, FGF is among the main targets to be 
analyzed in rodent models of  oval cell expansion. Indeed, 
aFGF (also known as FGF-1) is upregulated at the stage 
of  oval cell progression[89,100], being expressed by both oval 
cells and Ito cells. FGFR1 and FGFR2 are also expressed 
at high levels during the period of  active proliferation and 
differentiation of  oval cells, but exhibit a different pat-
tern. Although FGFR1 is mainly expressed in oval cells, 
FGFR2 is expressed in both oval and Ito cells[101]. These 
results suggest a differential role for these two receptors 
during liver stem/progenitor-cell-mediated regeneration, 
as well as the establishment of  both autocrine and para-
crine signaling. In addition to these in vivo observations, 
in vitro studies have shown that aFGF is able to push Met 
murine hepatocytes-bi-potential precursors isolated from 
transgenic livers, which express a constitutively active hu-
man Met - to progress from a very early state of  differen-
tiation to a more mature state, associated with the expres-
sion of  liver functions[47]. Moreover, FGF1-pretreated 
cells are resistant to the TGF-β dedifferentiation effect[102]. 
Essentially, FGFs have proved to be effective in mediating 
early hepatic differentiation, and therefore are included in 
most in vitro differentiation protocols[58]. 
TGF-β FAMILY
The TGF-β family of  cytokines regulates hepatocyte 
proliferation and death, and plays relevant roles during 
liver regeneration[103]. However, TGF-β and other pro-
inflammatory cytokines are important inducers of  fibro-
carcinogenesis, due to their ability to induce myofibro-
blast differentiation and ECM deposition[104,105]. Recent 
evidence has shown that TGF-β might also regulate liver 
stemness and phenotype[106].
TGF-β active form acts as a dimer, and signals by bring-
ing together two receptors with serine-threonine kinase 
activity, which are known as type Ⅰ and type Ⅱ receptors 
(Figure 2). After TGF-β binding, the type Ⅱ receptor 
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Figure 1  Schematic illustration of the major signaling pathways and biolog-
ical activities induced by hepatocyte growth factor and epidermal growth 
factor receptor ligands in liver progenitor cells. HGF: Hepatocyte growth 
factor; EGF: Epidermal growth factor; TGF: Transforming growth factor; STAT: 
Signal transducer and activator of transcription; PI3K: Phosphoinositide 3-ki-
nase; NF-κB: Nuclear factor κB; mTOR: Mammalian target of rapamycin; MEK: 
Mitogen-activated protein kinase kinase; ERKs: Extracellular-signal-regulated 
kinases.
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phosphorylates and activates the type Ⅰ receptor, which is 
responsible for phosphorylation of  the receptor-regulated 
Smad family of  transcription factors (R-Smads), i.e. Smad 
2 and 3 in the case of  TGF-β1, β2 and β3[107]. After phos-
phorylation, Smad 2 or 3 forms a complex with Smad 4 and 
shuttles to the nucleus, where it possesses DNA-binding 
activity, although it must associate with other DNA-binding 
co-factors to achieve high-affinity binding. Indeed, through 
combination with different transcription factors, the same 
TGF-β stimulus can induce or repress many different target 
genes. Activation of  the Smad transcriptional activity can 
be counteracted by the presence of  other members of  the 
Smad family that play inhibitory effects (inhibitory Smads), 
such as Smad 6 and Smad 7, which compete with Smad 
2 and 3 for binding either to the receptor complex or to 
Smad 4.
The most relevant Smad-mediated cell responses to 
TGF-β are growth inhibition and apoptosis. TGF-β in-
hibits proliferation in adult[108,109], as well as fetal or regen-
erating hepatocytes[82,109], and it is a well-known inducer 
of  hepatocyte cell death[110,111]. The inhibitory effects of  
TGF-β on liver stem/progenitor cell growth and survival 
are somewhat unclear. TGF-β overexpression results in 
impairment of  oval cell expansion induced by DDC[112]. 
Consistently, we have shown that treatment with TGF-β 
inhibits growth and induces apoptosis in DDC-derived 
oval cell lines in vitro[46]. However, when compared to adult 
hepatocytes, other authors have reported that the major-
ity of  the adult liver progenitor cells are more resistant to 
endogenously produced TGF-β anti-proliferative and pro-
apoptotic effects in vitro[113], which indicates a differential 
sensitivity to TGF-β between liver progenitors and ma-
ture hepatocytes. Indeed, several mechanisms have been 
proposed that would explain this differential response. 
On the one hand, the ratio between R-Smads and inhibi-
tory Smads might be different in oval cells. In this sense, 
Nguyen et al[114] have recently reported that oval cell lines 
show higher levels of  Smad 6 than do adult hepatocytes. 
On the other hand, oval cells might show over-activation 
of  survival signals, such as the MAPK/ERK pathway[115] 
that might be related to the autocrine production of  
growth/survival factors, such as HGF[46]. It is worth not-
ing that, when combined with growth factors such as 
EGF or HGF, TGF-β might contribute to cellular scat-
tering and morphological differentiation of  hepatoblasts 
and liver stem cells[87,116,117]. In this same line of  evidence, 
hepatocytes are undifferentiated and liver architecture 
is lost in Smad 2+/- and Smad 3+/- mice, as well as in 
ELF (a β-spectrin that is crucial for the propagation of  
the TGF-β signal) mutants[118-121]. Defects in Smad 2+/- 
and Smad 3+/- mutants are restored by HGF treatment. 
Although mechanisms by which TGF-β signals can be 
supplanted by HGF are unknown, data seem to support 
cooperation between two independent pathways, that con-
verge on β1-integrin expression, rather than direct path-
way crosstalk[119]. Emerging new data have reinforced the 
idea that TGF-β is important for stem cell transitioning to 
a progenitor cell phenotype, and ultimately, its conversion 
to a fully differentiated phenotype. Indeed, TGF-β signal-
ing, and particularly ELF, appears to play a crucial role in 
hepatocyte proliferation and transitional phenotype during 
human liver regeneration, and its loss is associated with 
activation of  liver progenitor cells[106]. It has also been 
shown recently that TGF-β might be a determinant in the 
appearance of  progenitor/stem cells in hepatocarcinogen-
esis. The examination of  human hepatocellular carcinoma 
(HCC) has revealed that cells that are labeled with stem-
cell markers have unexpectedly lost the TGF-β receptor 
Ⅱ and ELF, and show marked activation of  the IL-6 
pathway, a major stem-cell signaling pathway[121,122]. These 
data support that absence of  TGF-β-driven epithelial dif-
ferentiation favors carcinogenesis.
However, TGF-β is a pleiotropic cytokine inducing 
several, and sometimes contradictory, signals in epithe-
lial cells. Indeed, in addition to the well-known Smad-
mediated transcriptional responses that predominantly 
address tumor suppressor actions, TGF-β induces other 
Smad-dependent or independent effects that contribute to 
tumor progression[107]. Among these, related to the topic 
of  this review, one of  the more relevant is the capacity to 
induce EMT processes. EMT is a physiological process 
during embryogenesis, in which an epithelial cell loses ex-
pression of  adhesion molecules, such as E-cadherin, and 
other components responsible for cell polarity. Instead, 
they express mesenchymal components of  the cytoskel-
eton and acquire motility and scattering properties[123]. 
A closely related phenotypic conversion is also detected 
in fibrosis and neoplasia and is associated with disease 
progression[124]. Members of  the TGF-β family can initi-
ate and maintain EMT in a variety of  biological systems 
and pathophysiological situations, through activation of  
major signaling pathways and transcriptional regulators 
integrated in extensive signaling networks[125,126]. In cul-
ture, hepatocytes and hepatoma cells undergo EMT in 
response to TGF-β[127-130], which support a potentially cru-
cial role for TGF-β in the development and progression 
of  hepatic fibrogenesis and cancer. The mechanisms that 
allow cells to escape from the apoptotic effects of  TGF-β 
and undergo EMT are not completely understood. How-
ever, recent results have indicated that, in some epithelial 
cells, including fetal rat hepatocytes and hepatoma cells, 
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Figure 2  Overview of the major signaling pathways, and their cellular ef-
fects, induced by transforming growth factor-β in liver cells. TGF: Transform-
ing growth factor; EGFR: Epidermal growth factor receptor; ELF: Embryonic liver 
fodrin; TACE: Tumor necrosis factor-converting enzyme.
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TGF-β might induce both pro- and anti-apoptotic signals 
and their balance defines the cell fate[129,131-133]. In fact, 
certain evidence indicates a crosstalk between the genetic 
programs that control TGF-β-induced growth arrest/
apoptosis and those that regulate EMT, because once the 
cell has adopted a mesenchymal phenotype, it does not re-
spond to TGF-β suppressor effects[128,134,135]. Thus, TGF-β 
might regulate its own signaling to switch from tumor 
suppression to tumor progression. Indeed, it is interesting 
to point out that transcription factors of  the Snail family, 
repressors of  the E-cadherin gene, are required for cell 
survival during EMT[136,137]. 
In recent works from our group, we have demon-
strated that transdifferentiation of  liver cells from an 
epithelial to a mesenchymal phenotype, such as that me-
diated by TGF-β, induces dedifferentiation and allows 
enrichment in a population of  cells with putative liver 
progenitor properties[91,128,138]. The phenotypic character-
istics observed (elongated phenotype, strong expression 
of  Thy-1, vimentin or α-smooth muscle actin) are also 
highly reminiscent of  myofibroblasts[139]. These finding 
are in agreement with the recently proven fact that EMT 
not only endows cells with migratory and invasive proper-
ties, but also induces stem cell properties[123]. Furthermore, 
additional works have proved the capacity of  TGF-β to 
induce/maintain a stemness phenotype in other tissues[140]. 
Preliminary results have indicated that human fetal hepa-
tocytes respond to TGF-β downregulation of  E-cadherin 
and upregulation of  Snail, thus acquiring a fibroblastic-like 
morphology and a liver progenitor cell phenotype (unpub-
lished observations from our group in collaboration with 
Dr. N. Fausto, University of  Washington, Seattle, USA).
These findings might have implications for regenera-
tive biology of  the liver and open new perspectives for 
the in vitro isolation of  putative liver stem/progenitor cells 
to be used in basic and translational research in the liver. 
Moreover, a recent study has also suggested that TGF-β 
treatment of  HCC cells might induce the selection of  
cells expressing high levels of  CD133, a putative stem-cell 
marker in diverse hematopoietic and non-hematopoietic 
tissues and cancers[141], through a mechanism partially 
dependent on the Smads pathway, and that involves epi-
genetic regulation of  the CD133 promoter. These results 
indicate that TGF-β might also play a role in transdiffer-
entiating liver tumor cells to liver cancer stem cells.
In the embryo, progenitors to pancreatic β cells and 
hepatocyte lineages arise from neighboring domains of  
ventral foregut endoderm. It has been recently found that 
the specification of  pancreas and liver progenitors is re-
stricted by the TGF-β pathway[12]. It has been speculated 
that TGF-β signaling restrains lateral endoderm specifica-
tion until the cells move sufficiently far from the heart and 
into a bone morphogenetic protein signaling domain, with 
the latter then becoming the dominant Smad 4-dependent 
pathway, which leads to pancreatic induction. TGF-β sig-
naling appears to be strongly inhibitory to the pancreatic 
lineage and modestly inhibitory to the liver lineage, which 
suggests that TGF-β also plays a relevant role in maintain-
ing the stemness phenotype of  endodermal precursors 
during liver development.
All these results suggest a dual role for the TGF-β 
signaling pathway in liver stemness and differentiation. 
On the one hand, TGF-β mediates progression of  dif-
ferentiation from a stem or progenitor stage, but on the 
other hand, it contributes to the expansion of  liver stem 
cells. Further work is necessary to understand better the 
relevance of  both effects in liver development, regenera-
tion and carcinogenesis.
HEDGEHOG FAMILY LIGANDS 
Hedgehog (Hh) family ligands are widely acknowledged 
morphogens that regulate tissue remodeling during em-
bryogenesis[142,143]. In particular, Indian hedgehog and 
Sonic hedgehog ligands, and their receptor, Patched, are 
expressed at different stages of  liver organogenesis, and 
available data point to dynamic signal activation and tem-
porarily restricted effects on hepatoblast regulation. Thus, 
Hh signaling is necessary to promote hepatoblast prolif-
eration but it needs to be shut off  to permit subsequent 
hepatoblast differentiation[143-148]. Hh signaling is also 
involved in the maintenance of  a hepatic progenitor reser-
voir throughout life, both in humans and mice. Blockade 
of  Hh activity in hepatic progenitors in vitro decreases sur-
vival, whereas stimulation of  Hh activity inhibits endog-
enous apoptosis. Both autocrine and paracrine modes of  
action are suggested, based on simultaneous expression 
of  Hh ligands and receptors in liver progenitor cells[149]. 
Additional observations suggest that Hh pathway activa-
tion is a common feature of  various types of  chronic liver 
injury associated with mobilization of  hepatic progeni-
tor populations. Participation of  the Hh pathway has 
been demonstrated in the ductular reaction that is elicited 
by chronic alcohol-induced liver injury in mice and hu-
mans[150]; non-alcoholic steatohepatitis in humans[151]; me-
thionine choline-deficient ethionine-supplemented diet[152] 
and fatty liver damage[153] in mice. Hh ligands are released 
by hepatocytes and myofibroblasts, and lead to enhanced 
viability and proliferation of  bile ductular cells and hepatic 
progenitors, thus promoting the ductular response and 
fibrogenesis. Myofibroblasts, but not hepatocytes, also re-
spond to Hh ligands with an increase in viability[152,154-157]. 
Either Hh paracrine signaling between myofibroblast and 
hepatic progenitors or autocrine signaling, or both, pro-
mote EMT in hepatic progenitors, which ultimately con-
tributes to liver fibrosis[157-159].
The way in which Hh signaling interacts with other 
pathways to control the fate of  hepatic progenitor popu-
lations during liver repair after damage or neoplasia is 
still not well understood. Nonetheless, some interesting 
pieces of  information are emerging. Similar to that which 
has been described in embryogenesis[160], a functional 
crosstalk between the TGF-β and Hh signaling pathways 
has been proposed in the context of  adult liver progeni-
tor expansion during liver injury. In ethanol-fed mice, 
TGF-β induces production of  Hh ligands in hepatocytes, 
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which subsequently promotes survival and expansion of  
ductular/oval cell populations. This supports the concept 
that enhanced exposure to TGF-β contributes to the ac-
cumulation of  cells with a ductular phenotype, which are 
protected from TGF-β-mediated apoptosis[155,161]. Recip-
rocally, Hh-induced EMT might depend, at least partially, 
on induction of  TGF-β[159]. Further research is required to 
delineate the Hh-TGF-β interaction.
These findings suggest a role for the Hh pathway as a 
major mediator in the communication network established 
between myofibroblast and liver progenitors, which pro-
motes progenitor accumulation and contributes to hepatic 
fibrosis pathogenesis through EMT induction. 
WINGLESS/β-CATENIN PATHWAY
Proteins of  the wingless (Wnt) family are secreted signal-
ing molecules that regulate multiple processes in animal 
development and control tissue homeostasis. The Wnt sig-
naling pathway is highly conserved throughout evolution 
and plays essential roles in controlling cell proliferation, 
cell to cell adhesion, and motility[162]. In the liver, it plays 
many crucial roles during hepatic development and regen-
eration, and its dysregulation is evident in aberrant growth 
during hepatocarcinogenesis[163]. Wnt signaling is itself  
inherently complex[164]. On the one hand, both the ligands 
and receptors involved in Wnt signal transduction belong 
to large multi-gene families, which allows for a large num-
ber of  possible ligand-receptor interactions. On the other 
hand, Wnt-receptor interactions can elicit a variety of  
intracellular responses, the best-known of  which results in 
the activation of  β-catenin/T-cell factor (TCF) transcrip-
tional complexes. In the absence of  signals, β-catenin ac-
cumulates in adherens junctions and free β-catenin levels 
are very low because the tumor suppressor adenomatous 
polyposis coli forms a trimer complex with glycogen syn-
thase kinase-3-β and axin/conductin, which interacts with 
and phosphorylates β-catenin, thus targeting it for deg-
radation to the proteasome (Figure 3). Wnts bind a two-
part receptor: a seven transmembrane Frizzled and low-
density lipoprotein-related protein (LRP)5/6, both being 
required for canonical signaling. Ligand binding mediates 
phosphorylation of  the cytoplasmic tail of  LRP5/6, 
which creates an axin-binding site. Axin recruitment inac-
tivates the destruction complex. This stabilizes β-catenin, 
which enters into the nuclei where it displaces Groucho 
from TCF, nucleating formation of  a multiprotein activa-
tor complex, and activating Wnt target genes[165] (Figure 3). 
Furthermore, β-catenin is at the crossroads of  growth 
factor and cytokine signaling. Indeed, certain evidence 
indicates that TGF-β might induce nuclear β-catenin ac-
cumulation, through induction of  platelet-derived growth 
factor signaling[166]. β-catenin expression leads to elevated 
EGFR levels in hepatocytes and immunohistological 
analysis shows high correlation between the expression 
of  nuclear/cytoplasmic β-catenin and EGFR in most 
hepatoblastomas[167]. β-catenin also participates in ho-
motypic cell-cell interactions through its association with 
E-cadherin. Thus, nuclear β-catenin accumulation in HCC 
cells might contribute to impaired E-cadherin expression, 
which mediates the EMT process, migration and survival. 
It is also known that β-catenin and Met form a complex 
on hepatocyte membranes. Upon HGF stimulation, the 
complex is dissociated, in a β-catenin tyrosine phosphor-
ylation-dependent but Wnt-independent manner, which 
results in β-catenin nuclear translocation[168]. In addition, 
a role for β-catenin as a downstream effector of  HGF in 
HGF-induced hepatomegaly has been demonstrated[169]. 
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It has been recently suggested that oval cells respond 
to Wnt ligands in vitro with an increase in amino-terminus 
dephosphorylated β-catenin and cell cycle entry[170], and 
that canonical Wnt/β-catenin/TCF signaling plays a key 
role in the normal activation and proliferation of  adult 
hepatic stem cells[171,172]. In this same line of  evidence, 
repression of  Wnt/β-catenin signaling in the anterior en-
doderm is essential for liver and pancreas specification[173], 
which indicates that turning Wnt signaling off  is essential 
for liver differentiation. An opposite situation might be 
found during hepatocarcinogenesis, where reactivation of  
the Wnt/β-catenin pathway, or accumulation of  nuclear 
β-catenin due to other alterations might contribute to the 
expansion of  liver tumor stem cells. Indeed, recent reports 
have highlighted the relevance of  Wnt/β-catenin signaling 
in the activation of  tumorigenic liver progenitor cells[174] 
and the acquisition of  hepatic stem-cell markers[175] in 
HCC. Accumulation of  nuclear β-catenin has been shown 
to induce an early liver progenitor phenotype in HCC, 
which correlates with tumor recurrence[176].
In summary, Wnt family and β-catenin/TCF pathways 
are clearly involved in the maintenance of  the liver stem-
ness phenotype, and its repression is necessary for liver 
differentiation during development. Its overactivation dur-
ing liver tumorigenesis might contribute to the acquisition 
of  a liver cancer stem cell phenotype.
CONCLUSION
For the past 10-15 years, significant progress has been 
made in elucidating the cellular and molecular mecha-
nisms that contribute to control of  liver stem/progenitor 
cell behavior. Its complexity and multifaceted nature is 
evident. Among the diverse signaling pathways at play, the 
major growth factors, cytokines, and other ligand/recep-
tor systems known to play an important role in liver devel-
opment, homeostasis and regeneration, certainly occupy 
a central position. Many of  the classical responses elicited 
by these factors are conserved. However, differences in 
the downstream mechanisms following ligand-receptor 
engagement, or signal interaction and crosstalk, as well 
as specific alterations in intracellular mediators, are being 
identified as contributing factors to the differential re-
sponse of  liver stem/progenitor cells compared with their 
mature counterparts. In addition, besides delivery of  sig-
nals by the surrounding microenvironment, accumulating 
observations are pointing to co-existence of  paracrine and 
autocrine modes of  response as general regulatory mecha-
nisms on this cell population. Collectively, these data indi-
cate that liver stem/progenitor cells follow their own rules 
and regulations. It is also clear that the same signals that 
are essential for their activation, expansion, and differen-
tiation, are good candidates to contribute, under adequate 
conditions, to the paradigm of  transformation from a 
pro-regenerative to a pro-tumorigenic role. Unquestion-
ably, from a clinical perspective, this is a fundamental issue 
for liver/stem progenitor cell-based therapies. Despite the 
fact that additional efforts are required to delineate per-
fectly how the functional switch takes place, the studies 
summarized here are steps in the right direction.
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